Brazil-China seminar discusses bioinformatics, big data and precision medicine

7 May 2019

Researchers at the Beijing Institute of Genomics (BIG) have been to Fiocruz for the Brazil-China seminar on Bioinformatics, Big Data and Precision Medicine.

The activity was promoted by the Bioinformatics Center of the National Laboratory of Scientific Computation (LNCC), in partnership with Fiocruz, the National Institute for Cancer (Inca) and the Federal University of Rio de Janeiro (UFRJ).

At the time, Chinese and Brazilian scientists presented their research and discoveries in several areas of computing with application of large databases in life sciences, especially the area of Genomics, Bioinformatics and Precision Medicine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK